GUILDFORD, England, Sept. 28, 2015 /PRNewswire/ -- ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, is pleased to announce that the Medical University of Vienna, one of its Key Opinion Leaders, has published further highly encouraging results in support of the use of ANGLE's Parsortix system in the detection of ovarian cancer.
Further to the announcement on 21 April 2015, the Medical University of Vienna has extended the work undertaken and published results from its work with the Parsortix system at the European Cancer Congress European Society for Medical Oncology ECC 2015, 25-29 September 2015,Vienna ("ESMO"). ESMO is one of the world's largest and most influential cancer conferences with an estimated 20,000 participants.
The poster can be downloaded from the ANGLE website here http://www.angleplc.com/the-parsortix-system/download-files/. The poster describes the results of work using the Parsortix system with qPCR (quantitative real-time PCR analysis) for downstream analysis of circulating tumour cells ("Parsortix/qPCR").
The 65 patient study demonstrated the detection of ovarian cancer at 78/80% sensitivity with 100% specificity, offering the potential for a much more effective detection of ovarian cancer than traditional techniques. A larger RNA panel of markers used on a subset of patients yielded even higher sensitivity whilst retaining 100% specificity.
The new data reported at ESMO relates to a comparison of Parsortix/qPCR with conventional immune-fluorescent staining ("IF"). The main finding was that Parsortix/qPCR clearly out-performed conventional IF staining. This was particularly pronounced in ovarian cancer where IF was effective in only 25% of patients compared to 78/80% when using Parsortix/qPCR.
This work further substantiates the value of the Parsortix system and its applicability in detecting ovarian cancer. ANGLE is working with Medical University of Vienna and other leading cancer centres to demonstrate through clinical studies the capability to triage patients having surgery for abnormal pelvic mass into those with high and low risk of ovarian cancer so that they can receive appropriately targeted treatment.
ANGLE estimates that the ovarian cancer sales potential for the Parsortix system in Europe and the United States would be in excess of £300 million per annum.
Dr Eva Obermayr, Principal Investigator at the Medical University of Vienna, commented:
"The Parsortix technology clearly outperforms conventional immune-fluorescent staining. The use of qPCR with the Parsortix system is both highly sensitive and specific and offers the potential for a liquid biopsy (simple blood test) to diagnose ovarian cancer. This would greatly improve the standard of the care that can be offered to women with this condition."
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"Detection of ovarian cancer is ANGLE's first clinical application for our Parsortix system. The continued strong results from Medical University of Vienna are impressive."
For further information: www.angleplc.com
For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/
SOURCE ANGLE plc